{"title":"Herpes zoster infections: epidemiology, diagnostics, and prophylaxis in light of a growing clinical problem","authors":"P. Własiuk, Krzysztof Giannopoulos","doi":"10.5603/hicp.96862","DOIUrl":"https://doi.org/10.5603/hicp.96862","url":null,"abstract":"","PeriodicalId":479826,"journal":{"name":"Hematology in Clinical Practice","volume":"21 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140231927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There is an increased risk of atrial fibrillation in patients treated with Bruton’s tyrosine kinase inhibitors such as ibrutinib or acalabrutinib. The risk of this complication, as in the general population, increases with the age of patients and the coexistence of cardiovascular diseases. Due to the observed platelet dysfunction associated with the activity of ibrutinib, antithrombotic prophylaxis against stroke becomes an important clinical problem. The presence of potential interactions between ibrutinib and oral anticoagulant and additionally increased risk of bleeding determine specific therapeutic choices, which are described in the article.
{"title":"Antithrombotic prophylaxis in patients treated with Bruton’s tyrosine kinase inhibitors","authors":"Sebastian Szmit","doi":"10.5603/hcp.2023.0006","DOIUrl":"https://doi.org/10.5603/hcp.2023.0006","url":null,"abstract":"There is an increased risk of atrial fibrillation in patients treated with Bruton’s tyrosine kinase inhibitors such as ibrutinib or acalabrutinib. The risk of this complication, as in the general population, increases with the age of patients and the coexistence of cardiovascular diseases. Due to the observed platelet dysfunction associated with the activity of ibrutinib, antithrombotic prophylaxis against stroke becomes an important clinical problem. The presence of potential interactions between ibrutinib and oral anticoagulant and additionally increased risk of bleeding determine specific therapeutic choices, which are described in the article.","PeriodicalId":479826,"journal":{"name":"Hematology in Clinical Practice","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136026262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：